5:27 PM
 | 
Oct 02, 2012
 |  BC Extra  |  Clinical News

Sanofi Gaucher's therapy meets Phase III endpoints

Sanofi (Euronext:SAN; NYSE:SNY) and its Genzyme Corp. subsidiary said twice-daily eliglustat tartrate met the primary endpoint of reducing spleen volume from baseline to nine months vs. placebo in the Phase III ENGAGE trial to treat Type I Gaucher's disease...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >